MARKER THERAPEUTICS INC
MRKRNASDAQUS Equity
$1.15▲ $0.03 (+2.23%)
Market closed · at close1h—
24h▲ 2.2%
7d▲ 0.4%
14d▼ 6.1%
30d▼ 21.6%
1y▼ 7.7%
🏦Market Cap
$398.07B
Large Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
55
Weak
Trading Snapshot
- Day Range
- $1.13 – $1.17
- 52-Week Range
- —
- Volume
- $4.78B
- Avg Volume
- $4.50B
- Shares Outstanding
- —
- Next Earnings
- Sep 2, 2026
Fundamentals Snapshot
- Annual Revenue
- $36.52B
- Last Q Revenue
- $8.79B
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own MRKR
- ✓High-growth profile — revenue up +3.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 62% gross margin and 17% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$36.52B▲ +2.4% YoY
Gross Margin (TTM)
62.1%▲ +0.7% YoY
Operating Income (TTM)
$3.98B▲ +2.4% YoY
Free Cash Flow (TTM)
$6.14B▲ +2.4% YoY
About MARKER THERAPEUTICS INC
A company profile for MARKER THERAPEUTICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
55/100
Analyst Price Target
ⓘAverage Target
$1.18
▲ +3.1% Upside
High Target$1.33
Low Target$0.96
Based on 10 analysts
Latest News & Updates
🚀
MarketWatch·2h ago
MARKER THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Reuters·5h ago
Analysts lift MRKR price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
MarketWatch·1d ago
MARKER THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.